Loading
When a health system pays for a new, uncertain cancer drug, it would require that every patient's outcome is recorded and that a pre-agreed analysis decides whether payment continues.
Coverage with evidence development exists (the English Cancer Drugs Fund, Medicare CED, Italy's AIFA registries) but analyses are often weak, late or never published. The proposal standardises the model: a pre-registered statistical analysis plan agreed at listing, mandatory structured data capture, an independent analysis body, a fixed decision date, and publication of results whatever the outcome.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries, Prices and value.